Background: There are conflicting reports on the impact of HIV in the era of combined antiretroviral (c-ART) on survival of patient with ESKD. We aimed to compare the one-year survival of HIV positive patients to that of their HIV negative counterparts with ESKD on maintenance haemodialysis in Cameroon.
Methods: This was a retrospective cohort study conducted in the haemodialysis units of the Douala and Yaoundé General Hospitals. All HIV positive patients treated by maintenance haemodialysis between January 2007 and March 2015 were included. A comparative group of HIV negative patients with ESKD were matched for age, sex, co morbidities, year of dialysis initiation and haemodialysis unit. Relevant data at the time of haemodialysis initiation and during the first year of haemodialysis was noted. Survival was analysed using the Kaplan Meier and Cox regression hazard ratio estimator. A p value < 0.05 was considered statistically significant.
Results: A total of 57 patients with HIV and 57 without HIV were included. Mean age was 46.25 ± 11.41 years, and 52.6% were females in both groups. HIV nephropathy (50.9%) was the main presumed aetiology of ESKD in the HIV group, while chronic glomerulonephritis (33.3%) and diabetes (21.1%) were the main aetiologies in the HIV negative group. At initiation of dialysis, the median CD4 count was 212 cell/mm (IQR; 138-455) and 77.2% were receiving c-ART. The proportion of patients who initiated dialysis with a temporary venous catheter was similar in both groups (p = 0.06). After one year on haemodialysis, survival rate was lower in the HIV positive group compared to the HIV negative group (61.4%/78.9%, HR: 2.05; 95% CI: 1.03-4.08; p = 0.042).Kaplan Meier survival curve was in direction of a lower survival in HIV positive group (p = 0.052).
Conclusion: The one year survival of HIV positive patients on maintenance haemodialysis in Cameroon seems to be lower compared to their HIV negative counterparts.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034298 | PMC |
| http://dx.doi.org/10.1186/s12882-018-0964-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ventriculoperitoneal shunt in the treatment of cryptococcal meningitis with intracranial hypertension.
J Infect Dev Ctries
December 2024
Department of Neurosurgery, The third affiliated hospital, Sun Yat-Sen University, Guangzhou, China.
Introduction: Cryptococcal meningitis (CM) combined with intracranial hypertension is associated with a poor prognosis. This study aimed to investigate the therapeutic efficacy and prognostic factors of ventriculoperitoneal (VP) shunt in non-human immunodeficiency virus (HIV) CM patients with intracranial hypertension.
Methodology: A total of 136 non-HIV CM patients with intracranial hypertension treated in our hospital from July 2010 to December 2019 were retrospectively included.
Magnitude of Depression and Associated Factors in Women Living With HIV in Northwest, Ethiopia: Mediation Analysis.
AIDS Res Treat
January 2025
Department of Health Promotion and Behavioral Sciences, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Depression in women living with HIV (WLWHIV), is one of the most common public health concerns worldwide. Depression has a negative impact on antiretroviral therapy (ART) adherence, quality of life, poor HIV treatment outcomes, and mortality. However, there is a paucity of evidence in low-income countries such as Ethiopia in WLWHIV.
View Article and Find Full Text PDFImmune Reconstitution Inflammatory Syndrome-Induced Thrombocytopenia in a Patient With HIV and Coccidioidomycosis.
Cureus
December 2024
Internal Medicine, Kern Medical, Bakersfield, USA.
Highly active antiretroviral therapy (HAART) is imperative in managing human immunodeficiency virus (HIV) infections. HAART aims to inhibit viral replication and improve immunity. Antiretroviral therapy has led to significant improvement in CD4-T cell counts and reductions in viral load, leading to improved overall immune function, increased survival, and decreased frequency of opportunistic infections.
View Article and Find Full Text PDFThe Linda Kizazi study: a comparison of morbidity and mortality from birth to 2 years between children who are HIV-unexposed and HIV-exposed, uninfected in the era of universal antiretroviral therapy.
BMJ Glob Health
January 2025
Paediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Background: Historically, children who are HIV-exposed, uninfected (CHEU) have been found to have greater morbidity and mortality than children who are HIV-unexposed, uninfected (CHUU). To assess whether this difference persists in the era of universal antiretroviral therapy (ART), we conducted a cohort study to compare the risk of acute diarrhoea, respiratory tract infections (RTI), malaria, hospitalisation, and all-cause mortality between Kenyan CHEU and CHUU from birth to 2 years.
Methods: From December 2018 to March 2020 at Mathare North Health Centre in Nairobi, we recruited pregnant women living with HIV on ART for ≥6 months and pregnant women without HIV from the same community.
Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications.
Mol Neurodegener
January 2025
Research Center for Neuroscience, Taipei Medical University, Taipei, Taiwan.
Chitinase-3-like-1 (CHI3L1) is an evolutionarily conserved protein involved in key biological processes, including tissue remodeling, angiogenesis, and neuroinflammation. It has emerged as a significant player in various neurodegenerative diseases and brain disorders. Elevated CHI3L1 levels have been observed in neurological conditions such as traumatic brain injury (TBI), Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease (CJD), multiple sclerosis (MS), Neuromyelitis optica (NMO), HIV-associated dementia (HAD), Cerebral ischemic stroke (CIS), and brain tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!